GRAIL to Announce Third Quarter 2024 Financial Results

GRALV 10.29.2024

SERA-AI Powered Highlights
Full Press ReleaseSEC FilingsOur GRALV Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Patient Reported Outcomes for GRAIL's Galleri® Multi-Cancer Early Detection Blood Test Published in Lancet Oncology
  • 12.18.2024 - GRAIL to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

    MENLO PARK, Calif.,Oct. 29, 2024/PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the third quarter 2024 following the close of market onTuesday, Nov. 12, 2024. Following the release, company management will host a webcast and conference call at1:30 p.m. PT/4:30 p.m. ETto discuss results and business progress.

    GRAIL, Inc. is a healthcare company whose mission is to detect cancer early when it can be cured. (PRNewsfoto/GRAIL, Inc.)

    Third Quarter 2024 Webcast and Conference Call DetailsA link to the live webcast and recorded replay will be available at the investor relations section of GRAIL's website atinvestors.grail.com.

    Please register for the live event athttps://grail-q3-financial-results-2024.open-exchange.net/.

    To ensure timely connection, please register for the teleconference and join the webcast at least ten minutes before the scheduled start of the call. The live webcast and recorded replay are open to all interested parties.

    About GRAILGRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered inMenlo Park, CAwith locations inWashington, D.C.,North Carolina, and theUnited Kingdom.

    For more information, visitgrail.com.

    CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-announce-third-quarter-2024-financial-results-302290446.html

    SOURCEGRAIL, Inc.

    GRAIL Contacts: Corporate Communications: Kristen Davis or Trish Rowland, pr@grail.com; Investor Relations: Alex Dobbin or Alexis Tosti, ir@grail.com

    Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com